Sanofi | SNY - Gross Profit On Sales


Sanofi reported EUR8.45B in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Genmab DKK 868M 195M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pacira USD 130.92M 5M Sep/2025
Perrigo USD 377.1M 14.2M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Phibro Animal Health USD 101.87M 18.38M Dec/2024
Prestige Brands USD 157.37M 5.79M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sanofi EUR 8.45B 3.02B Dec/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
UCB EUR 2.46B 520M Dec/2024
Zoetis USD 1.64B 73M Dec/2025